A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib

Triple negative breast cancers (TNBC) have poor prognosis compared to other breast cancer subtypes and represent 15-20% of breast cancers diagnosed. Unique targets and new molecularly-targeted therapies are urgently needed for this subtype. Despite high expression of Epidermal Growth Factor Receptor...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Ebelt, Nancy D., Kaoud, Tamer S., Edupuganti, Ramakrishna, Van Ravenstein, Sabrina, Dalby, Kevin N., Van Den Berg, Carla L.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739608/
https://ncbi.nlm.nih.gov/pubmed/29285221
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.20581
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires